Different immune responses to three different vaccines following H6N1 low pathogenic avian influenza virus challenge in Taiwanese local chicken breeds.

BACKGROUND: H6N1 low pathogenic avian influenza virus (LPAIV) are frequently isolated in Taiwan and lead to significant economic losses, either directly or indirectly through association with other infectious diseases. This study investigates immune responses to three different vaccines following a H6N1 challenge in different local breeds. METHODS: Experimental animals were sampled from six local chicken breeds maintained at the National Chung-Hsing University, namely Hsin-Yi, Ju-Chi, Hua-Tung (Taiwan), Quemoy (Quemoy Island), Shek-Ki (China), Nagoya (Japan) and a specific pathogen free (SPF) White Leghorn line. A total number of 338 chickens have been distributed between a control and a challenge group, H6N1 challenge was performed at 7 weeks of age; vaccination against Newcastle Disease (ND), Infectious Bursal Disease (IBD) and Infectious Bronchitis (IB) was performed at 11 weeks. The anti-H6N1 LPAIV antibody titers were measured by ELISA at days 0, 7, 14 and 21 after challenge, and the anti-ND, anti-IBD and anti-IB antibody titers were measured by inhibition of hemagglutination test and ELISA at days 0, 14, 28 after vaccination. RESULTS: There was no effect of the H6N1 LPAIV challenge at 7 weeks of age on the subsequent responses to ND and IBD vaccine at 11 weeks of age, but, surprisingly, the H6N1 LPAIV challenge significantly affected antibody levels to IB vaccine in some breeds, since IB0 and IB14 antibody titers were lower in the challenge groups. However, there was no significant difference in IB28 antibody titers among the experimental groups. CONCLUSIONS: Local breeds have different immune response to H6N1 LPAIV challenge and subsequent vaccines. Differences dealt mainly with kinetics of response and with peak values. Quemoy exhibited higher antibody levels to H6N1, ND and IBD. The negative effect of the H6N1 LPAIV challenge on IB vaccine response may be related to the fact that both viruses target the lung tissues, and the type of local immune response induced by LPAIV challenge may not be favourable for birds to make optimum IB-specific antibody response.RIGHTS : This article is licensed under the BioMed Central licence at http://www.biomedcentral.com/about/license which is similar to the 'Creative Commons Attribution Licence'. In brief you may : copy, distribute, and display the work; make derivative works; or make commercial use of the work - under the following conditions: the original author must be given credit; for any reuse or distribution, it must be made clear to others what the license terms of this work are

Subunit vaccine of Pasteurella multocida in veterinary uses

The present invention declaims the use of Pasteurella lipoprotein E (PlpE) as a subunit vaccine and the use of vaccines containing PlpE to protect animals from diseases caused by P. multocida. The results of vaccination and challenge experiments showed that mice and chickens immunized with PlpE were completely protected animals from challenge infection with 10.sup.1-10.sup.3 LD.sub.50 of P. multocida and no adverse effect was observed

Preparation of Chicken Anemia Virus (CAV) Virus-Like Particles and Chicken Interleukin-12 for Vaccine Development Using a Baculovirus Expression System

Chicken infectious anemia (CIA) is a poultry disease that causes huge economic losses in the poultry industry worldwide. Commercially available CIA vaccines are derived from wild-type chicken anemia viruses (CAVs) by serial passage in cells or chicken embryos. However, these vaccinal viruses are not completely attenuated; therefore, they can be transmitted vertically and horizontally, and may induce clinical symptoms in young birds. In this study, we sought to eliminate these issues by developing a subunit vaccine exploiting the CAV structural proteins, engineering recombinant baculovirus-infected Spodoptera frugiperda (Sf9) cells that contained both the viral protein 1 (VP1) and VP2 of CAV. Moreover, we produced single-chain chicken interleukin-12 (chIL-12) in the same system, to serve as an adjuvant. The recombinant VP1 was recognized by chicken anti-CAV polyclonal antibodies in Western blotting and immunofluorescence assays, and the bioactivity of the recombinant chIL-12 was confirmed by stimulating interferon-γ (IFN-γ) secretion in chicken splenocytes. Furthermore, the ability of the recombinant VP1 to generate self-assembling virus-like particles (VLPs) was confirmed by transmission electron microscopy. Specific pathogen-free (SPF) chickens inoculated with VLPs and co-administered the recombinant chIL-12 induced high CAV-specific antibodies and cell-mediated immunity. Taken together, the VLPs produced by the baculovirus expression system have the potential to be a safe and effective CIA vaccine. Finally, we demonstrated the utility of recombinant chIL-12 as an adjuvant for poultry vaccine development

multocida) 次單位疫苗 SUBUNIT VACCINE OF PASTEURELLA MULTOCIDA IN VETERINARY USES

本發明係關於巴斯德桿菌Pasteurellamultocida脂蛋白E(Pasteurella lipoprotein E, PlpE)用作為次單位疫苗之用途。本發明更進一步係關於用於防治巴斯德桿菌P. multocida所引起之感染疾病的疫苗組成物，其包含脂蛋白E為主要組成。經動物實驗結果發現，本發明之次單位疫苗在施打小鼠及雞隻後，能產生良好的保護效力，可耐過101-103 LD50之P. multocida感染，且施打後無不良副作用

Molecular Characterization and Pathogenicity of the Novel Recombinant Muscovy Duck Parvovirus Isolated from Geese

Goose parvovirus (GPV) and Muscovy duck parvovirus (MDPV) are the main agents associated with waterfowl parvovirus infections that caused great economic losses in the waterfowl industry. In 2020, a recombinant waterfowl parvovirus, 20-0910G, was isolated in a goose flock in Taiwan that experienced high morbidity and mortality. The whole genome of 20-0910G was sequenced to investigate the genomic characteristics of this isolate. Recombination analysis revealed that, like Chinese rMDPVs, 20-0910G had a classical MDPV genomic backbone and underwent two recombination events with classical GPVs at the P9 promoter and partial VP3 gene regions. Phylogenetic analysis of the genomic sequence found that this goose-origin parvovirus was highly similar to the circulating recombinant MDPVs (rMDPVs) isolated from duck flocks in China. The results of experimental challenge tests showed that 20-0910G caused 100% mortality in goose embryos and in 1-day-old goslings by 11 and 12 days post-inoculation, respectively. Taken together, the results indicated that this goose-origin rMDPV was closely related to the duck-origin rMDPVs and was highly pathogenic to young geese

RECOMBINANT HAEMAGGLUTININ VACCINE FOR INFECTIOUS CORYZA OF CHICKENS, AND METHODS OF PREPARATION AND USE THEREOF

本發明係關於一種用於防治雞傳染性鼻炎之疫苗，其包含雞傳染性鼻炎菌(Avibacterium paragallinarum)之重組血球凝集素蛋白，該重組蛋白特徵在於包含一高度變化區序列。本發明進一步提供用於製備該重組血球凝集素疫苗之方法，包含以大腸桿菌生產包含該高度變化區序列之重組血球凝集素蛋白，以及將所得之重組蛋白作為有效之疫苗組成，以保護雞隻對抗雞傳染性鼻炎菌之感染

multocida)次單位疫苗 SUBUNIT VACCINE OF PASTEURELLA MULTOCIDA IN VETERINARY USES

本發明係關於巴斯德桿菌Pasteurella multocida脂蛋白E(Pasteurella lipoprotein E,PlpE)用作為次單位疫苗之用途。本發明更進一步係關於用於防治巴斯德桿菌P.multocida所引起之感染疾病的疫苗組成物,其包含脂蛋白E為主要組成。經動物實驗結果發現,本發明之次單位疫苗在施打小鼠及雞隻後,能產生良好的保護效力,可耐過10^1-10^3 LD50之P.multocida感染,且施打後無不良副作用